Showing results (441-450 of 824) with videos related to
Sort By:
Pageof 83
Leukemia|May 29, 2021
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myelomaSaad Z Usmani, Chatchada Karanes, William I Bensinger, et al.Haematologica|July 5, 2006
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib aloneSundar Jagannath, Paul G Richardson, Bart Barlogie, et al.Proteomics|March 3, 2011
A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patientsRajesh Rajpal, Paul Dowling, Justine Meiller, et al.Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in ChinaTengteng Yu, Yan Xu, Gang An, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cellJooeun Bae, Constantine Mitsiades, Yu-Tzu Tai, et al.Leukemia|July 22, 2021
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myelomaJooeun Bae, Fabrizio Accardi, Teru Hideshima, et al.JACC. Advances|May 15, 2025
Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert ConsensusNicole K Bart, Giada Bianchi, Sarah A M Cuddy, et al.European Journal of Haematology|October 14, 2011
The Medical Research Council Myeloma IX trial: the impact on treatment paradigmsPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.Leukemia Research|April 16, 2013
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myelomaPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.Pageof 83